Skip to content

Relationship Between Dopaminergic Asymmetric Degeneration and Attentional Resources in Parkinson's Disease.

Relationship Between Dopaminergic Asymmetric Degeneration and Attentional Resources in Parkinson's Disease.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03476668
Acronym
RTsAsMIRT
Enrollment
100
Registered
2018-03-26
Start date
2017-01-01
Completion date
2017-08-01
Last updated
2018-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Disturbances, Parkinson Disease

Brief summary

The researchers aimed to investigate the relationship between the asymmetric dopaminergic degeneration and the attentional resources in a group of patients with Parkinson's disease (PD).

Detailed description

To bypass the impaired habitual motor-behavioural control, Parkinson's disease (PD) patients may exploit the network of goal-directed mode of action. The frontostriatal connections underline this functioning, that is based on attention. Since the cognitive processes are related with dopamine, the asymmetrical degeneration of the dopaminergic system affects differently the right side affected (RPD) and the left side affected (LPD) PD patients. The aim of the study was to investigate the relationship between the asymmetric dopaminergic degeneration and the attentional resources in a group of patients with PD.

Interventions

OTHERMIRT

4-week multidisciplinary intensive rehabilitation treatment

Sponsors

Ospedale Generale Di Zona Moriggia-Pelascini
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Stage 2.5-3 according to the Hoehn and Yahr scale (H&Y); * Stable pharmacological treatment for the last 6 weeks before the enrolment and during the hospitalization; * Mini Mental State Examination (MMSE) ≥ 24; * No evidences of dysexecutive syndrome.

Exclusion criteria

* Any focal brain lesion detected in brain imaging studies (CT or MRI) performed in the previous 12 months; * Drug-induced dyskinesias; * Disturbing resting and/or action tremor, corresponding to scores 2-4 in the specific items of UPDRS III; * Behavioral disturbances (evaluated with Neuropsychiatric Inventory); * Visual and auditory dysfunctions according to the general clinical evaluation and medical history; * Equivocal report about the side of disease onset or bilateral motor involvement.

Design outcomes

Primary

MeasureTime frameDescription
Visual Reaction Times (V RTs)4 weeksVisual Reaction Times
Auditory Reaction Times (A RTs)4 weeksAuditory Reaction Times
Multiple Choices RTs (MC RTs)4 weeksMultiple Choices RTs

Secondary

MeasureTime frameDescription
Unified Parkinson's Disease Rating Scale (UPDRS)4 weeksUnified Parkinson's Disease Rating Scale
Timed Up and Go Test (TUG)4 weeksTimed Up and Go Test

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026